Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MVA-PSA/PAP/STEAP1/5T4 prostate cancer vaccine MVA-PCAQ

A cancer vaccine consisting of recombinant replication-deficient modified vaccinia Ankara (MVA) viral vector encoding genes for the prostate cancer-associated antigens prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), six-transmembrane epithelial antigen of the prostate 1 (STEAP1), and 5T4 oncofetal antigen, with potential immunostimulatory and antineoplastic activities. Upon administration, MVA-PSA/PAP/STEAP1/5T4 prostate cancer vaccine MVA-PCAQ expresses PSA, PAP, STEAP1 and 5T4 peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing these antigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MVA-PCAQ
recombinant MVA PSA/PAP/STEAP1/5T4 vaccine MVA-PCAQ
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search